Unit Price:
৳ 11.50
(5 x 10: ৳ 575.00)
Strip Price:
৳ 115.00
Also available as:
Indications
Healing of Erosive Esophagitis: Dexogut is indicated for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks.
Maintenance of Healed Erosive Esophagitis: Dexogut is indicated to maintain healing of EE and relief of heartburn for up to 6 months.
Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexogut is indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.
Maintenance of Healed Erosive Esophagitis: Dexogut is indicated to maintain healing of EE and relief of heartburn for up to 6 months.
Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexogut is indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.
Pharmacology
Dexlansoprazole delayed-release capsule is a Proton Pump Inhibitor (PPI) which suppresses gastric acid secretion by specific inhibition of the (H+/K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlansoprazole blocks the final step of acid production. It is the R-enantiomer of lansoprazole (A racemic mixture of the R- and S-enantiomers). Dexlansoprazole is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. This capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles. The dual delayed release formulation in dexlansoprazole, plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. After oral administration, mean Cmax and AUC value of Dexlansoprazole increased approximately dose proportionally. Dexlansoprazole is extensively metabolized in the liver and excreated by urine.
Dosage
Dexlansoprazole dosing recommendations-
- Maintenance of Healed erosive esophagitis and relief of heartburn: 30 mg Once daily
- Symptomatic Non-Erosive GERD: 30 mg Once daily for 4 weeks
- Healing of erosive esophagitis: 60 mg Once daily for up to 8 weeks
- Maintenance of healed erosive esophagitis and relief of heartburn: One 30 mg tablet once daily for 6 months in adults and 16 weeks in patients 12 to 17 years of age
- Symptomatic Non-Erosive GERD: One 30 mg tablet once daily for 4 weeks
* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Administration
Dexlansoprazole can be taken without regard to food. It should be swallowed whole.
Alternatively, Dexlansoprazole capsules can be administered as follows:
If a capsule is missed at its usual time, it should be taken as soon as possible. But if it is too close to the time of the next dose, only the prescribed dose should be taken at the appointed time. A double dose should not be taken.
Alternatively, Dexlansoprazole capsules can be administered as follows:
- Open capsule
- Sprinkle intact granules on one tablespoon
- Swallow immediately.
If a capsule is missed at its usual time, it should be taken as soon as possible. But if it is too close to the time of the next dose, only the prescribed dose should be taken at the appointed time. A double dose should not be taken.
* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Interaction
With medicine: Atazanavir, Warfarin, Tacrolimus, Clopidogrel & Methotrexate. With food & others: No data available.
Contraindications
Dexlansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation.
Side Effects
Common side effects: Diarrhea, abdominal pain, nausea, vomiting & flatulence.
Pregnancy & Lactation
Pregnancy Category B. There is no adequate and well-controlled studies with Dexlansoprazole in pregnant women. There is no adequate and well-controlled studies with Dexlansoprazole in Lactating mother.
Precautions & Warnings
Gastric Malignancy, Clostridium difficile Associated Diarrhea, Bone fracture, Hypomagnesemia, and concomitant use of Dexogut with Methotrexate.
Use in Special Populations
Use in children & adolescents: Safety and effectiveness of Dexogut in patients below 12 years age have not been established.
Geriatric use: No dose adjustment is necessary for elderly patients.
Renal impairment: No dose adjustment of Dexogut is necessary for patients with renal
impairment.
Hepatic impairment: No dose adjustment for Dexogut is necessary for patients with mild hepatic impairment. A maximum daily dose of Dexogut 30 mg should be considered for patients with moderate hepatic impairment.
Geriatric use: No dose adjustment is necessary for elderly patients.
Renal impairment: No dose adjustment of Dexogut is necessary for patients with renal
impairment.
Hepatic impairment: No dose adjustment for Dexogut is necessary for patients with mild hepatic impairment. A maximum daily dose of Dexogut 30 mg should be considered for patients with moderate hepatic impairment.
Overdose Effects
There have been no reports of a significant overdose of Dexogut. Multiple doses of Dexogut 120 mg and a single dose of Dexogut 300 mg did not result in death or other severe adverse events.
Therapeutic Class
Proton Pump Inhibitor
Storage Conditions
Store below 30°C temperature & in a dry place, protected from light. Keep all medicines out of reach of children.